summaris key newsflow snippet week interest
european large-cap pharma stock coverag
darzalex us line approv could immin rtor roll sbla submit
genmab partner complet roll sbla submiss fda
darzalex revlimid-dex line multipl myeloma mm file real-
time oncolog review pilot programm approv could swift preced set
kisqali approv within month adcetri approv week sbla
submiss meanwhil initi phase ii studi evalu retreat
subcutan darzalex relapsed/refractori mm patient previous treat
iv darzalex
roch us fda approv japanes file
late last week us fda approv roch tecentriq combin abraxan
unresect local advanc metastat tnbc follow week
eu approv hemlibra non-inhibitor haemophilia patient subsidiari chugai
file nda japan inhibitor entrectinib treatment
nsclc follow file ntrk tumour dec meanwhil us fda
approv fourth biosimilar herceptin trazimera assum us
biosimilar eros rituxan sale
news astrazenenca enter three year research collabor
focus microbiom potenti improv
respons cancer immunotherapi sell large-scal biolog
manufactur site denmark fujifilm perhap increas potenti futur
competit pressur lonza win large-scal antibodi product contract
us fda approv sanofi dupix atop dermat adolesc
bavarian nordic announc month delay us fda review mva-
bn smallpox vaccin decis expect septemb bava remain
elig prioriti review voucher approv richard franci step
ceo novarti sandoz cite inabl commit durat sandoz
transit autonom unit head europ francesco balestrieri
appoint interim ceo novarti agre outcome-bas price deal
germani car-t therapi kymriah treat
research publish week
wrap novarti inaugur swiss healthcar summit
novarti eagerli await zolgensma launch peg alcon equiti spin
lonza updat snippet annual report
cosmo methylen blue cosmo accept defeat start plan phase
oxb solid fundament predict catalyst
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
import disclosur inform compani recommend report pleas visit websit http //
javatar bluematrix com/sellside/disclosur action call
peter welford cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
colin white phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
philippa gardner eng certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli
indirectli relat specif recommend view express research report
luci codrington certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
registr non-u analyst peter welford cfa employ jefferi intern limit non-u affili jefferi
llc registered/qualifi research analyst finra analyst may associ person jefferi
llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst colin white phd employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
registr non-u analyst philippa gardner eng employ jefferi intern limit non-u affili
jefferi llc registered/qualifi research analyst finra analyst may associ person
jefferi llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst luci codrington employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom
seek updat research appropri variou regul may prevent us asid certain industri
report publish period basi larg major report publish irregular interv appropri analyst
articl articl
jefferi llc act financi advisor nightstar therapeut plc announc acquisit biogen inc
jefferi intern limit act financi advisor aurobindo pharma limit acquisit us asset
sandoz inc divis novarti
jefferi group llc make market secur adr astrazeneca plc
jefferi group llc make market secur adr biogen inc
jefferi group llc make market secur adr erytech pharma
jefferi group llc make market secur adr oxford biomedica plc
jefferi group llc make market secur adr sanofi
pleas see import disclosur inform page report
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic cosmo
within past twelv month cosmo client jefferi llc invest bank servic
jefferi group llc affili subsidiari act manag co-manag underwrit placement
secur cosmo one affili within past twelv month
jefferi group llc affili subsidiari benefici own common equiti erytech pharma last
month end prior month end report date later day recent month end
import disclosur inform compani recommend report pleas visit websit http //
javatar bluematrix com/sellside/disclosur action call
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold
rate secur averag secur price consist expect total return price appreci plu yield
plu minu within period under-perform rate secur averag secur price consist
expect total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi
project opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf
averag group price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month
period stock select base fundament analysi may take account factor analyst convict
differenti analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi
franchis pick includ buy rate stock number vari depend analyst recommend inclus
stock ad new opportun aris remov reason inclus chang stock met desir
return longer rate buy and/or trigger stop loss stock day volatil bottom quartil
stock continu stop loss remaind stop franchis pick intend repres
recommend portfolio stock sector base may note believ pick fall within invest
style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
pleas see import disclosur inform page report
deem necessari past perform financi instrument recommend report taken
indic guarante futur result price valu incom financi instrument mention
report rise well fall may affect chang econom financi polit factor financi instrument
denomin currenc investor home currenc chang exchang rate may advers affect price
valu incom deriv financi instrument describ report addit investor secur adr
whose valu affect currenc underli secur effect assum currenc risk
compani mention report
distribut rate
distribut rate
pleas see import disclosur inform page report
